REVERSED

1700 Chemical & Materials Engineering
1732 Ex Parte Bastelberger et al 10/557,658 FRANKLIN 103(a) BROOKS KUSHMAN P.C. EXAMINER NGUYEN, COLETTE B

AFFIRMED-IN-PART

1700 Chemical & Materials Engineering
1731 Ex Parte Barnes et al 10/899,452 COLAIANNI 102(b)/103(a)/nonstatutory obviousness-type double patenting AUTOLIV ASP, INC ATTN: SALLY J. BROWN, ESQ EXAMINER MCDONOUGH, JAMES E

2600 Communications
2612 Ex Parte Copeland et al 10/ 037,337 HAHN 103(a) Christopher & Weisberg, P.A. EXAMINER LEE, BENJAMIN C

REEXAMINATION

3900 Central Reexamination Unit (CRU)
2132 Ex parte TSE Ho Keung Appellant and Patent Owner 90/008,772 6,665,797 TURNER 102(b)/102(e)/103(a) PATENT OWNER: HO KEUNG TSE THIRD-PARTY REQUESTER: MORRISON & FOESTER LLP EXAMINER HENEGHAN, MATTHEW E original EXAMINER BARRON JR, GILBERTO

AFFIRMED

1600 Biotechnology and Organic Chemistry
1611 Ex Parte Rollat-Corvol et al 10/320,707 GRIMES 103(a) NIXON & VANDERHYE, PC EXAMINER FRAZIER, BARBARA S

1626 Ex Parte Villamar et al 10/312,039 PRATS 102(b)/103(a) THE VILLAMAR FIRM PLLC EXAMINER NWAONICHA, CHUKWUMA O

1651 Ex Parte Feng 10/460,577 FREDMAN 103(a) KNOBBE MARTENS OLSON & BEAR LLP EXAMINER ZERVIGON, RUDY EXAMINER FORD, ALLISON M

1656 Ex Parte Lee et al 10/848,689 GRIMES 102(b)/103(a)/obviousness-type double patenting HUGH MCTAVISH MCTAVISH PATENT FIRMEXAMINERKIM, ALEXANDER D

1615 Ex Parte Bosch et al 10/619,539 LEBOVITZ 102(b)/102(e)/103(a)/112(1)/112(2) Elan Drug Delivery, Inc. c/o Foley & Lardner
EXAMINER TRAN, SUSAN T

1700 Chemical & Materials Engineering
1716 Ex Parte Elers 10/867,890 COLAIANNI 102(b)/103(a) KNOBBE MARTENS OLSON & BEAR LLP EXAMINER ZERVIGON, RUDY

1783 Ex Parte Wong et al 11/528,884 COLAIANNI Concurring-in-Part, Dissenting-in-Part KRATZ 103(a) THE PROCTER & GAMBLE COMPANY EXAMINER LONEY, DONALD J

2100 Computer Architecture and Software
2165 Ex Parte Lillibridge et al 10/988,415 DANG 102(b)/103(a)/101 HEWLETT-PACKARD COMPANY EXAMINER HOANG, SON T

2400 Networking, Mulitplexing, Cable, and Security
2439 Ex Parte Brown et al 10/602,754 MARTIN 102(b)/103(a) ROBERT D. SHEDD, PATENT OPERATIONS
THOMSON LICENSING LLC EXAMINER TOLENTINO, RODERICK

2443 Ex Parte Hind et al 10/460,929 LUCAS 102(e)/103(a) RSW IP Law IBM CORPORATION EXAMINER ENGLAND, DAVID E

2421 Ex Parte Kurapati et al 10/179,313 NAPPI 112(1)/102(b)/103(a)/101 PHILIPS INTELLECTUAL PROPERTY & STANDARDS EXAMINER MONTOYA, OSCHTA I

2600 Communications
2612 Ex Parte Lippincott 10/973,223 HOFF 103(a) JOSEPH P. CURTIN EXAMINER LU, SHIRLEY

2800 Semiconductors, Electrical and Optical Systems and Components
2822 Ex Parte Yamazaki 10/045,902 6,180,991 HORNER Concurring HANLON BAHR 251 ROBINSON INTELLECTUAL PROPERTY LAW OFFICE, P.C.EXAMINER POTTER, ROY KARL

We take this opportunity to resolve a conflict within the Office as to the meaning of “the term of the original patent” in 35 U.S.C. § 251 and whether the Office is authorized by this statute to remove a terminal disclaimer during reissue resulting in an expansion of the term of the original patent set at issuance. We interpret “the term of the original patent” in § 251 to refer to the “term” of the patent as the term set upon issuance of the original patent. As we noted supra, the Federal Circuit has recognized that under § 253 the expiration date of the patent subject to the terminal disclaimer is “reset” to the expiration date of the patent referenced in the terminal disclaimer. See Merck & Co., 482 F.3d at 1319; see also Bayer AG, 298 F.3d at 1381. Thus, we disagree with the Board’s earlier holding in Durckheimer that a terminal disclaimer does not alter “the term of the original patent.”

3600 Transportation, Construction, Electronic Commerce, Agriculture, National Security, and License & Review
3694 Ex Parte Grainger et al 09/872,764 FETTING 102(a)/103(a) KILPATRICK TOWNSEND & STOCKTON LLP EXAMINER CHEUNG, MARY DA ZHI WANG

3700 Mechanical Engineering, Manufacturing, and Products & Design
3725 Ex Parte Arnoldy 10/269,236 FETTING 101 PAULY, DEVRIES SMITH & DEFFNER, L.L.C. EXAMINER LEWIS, JUSTIN V

3769 Ex Parte Dycus et al 10/369,894 PRATS 112(1)/103(a) TYCO HEALTHCARE GROUP LP EXAMINER ROANE, AARON F

3771 Ex Parte Patton et al 10/693,318 GREEN 103(a) NOVARTIS EXAMINER MATTER, KRISTEN CLARETTE